Celcuity ( (CELC) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Celcuity shares slid despite the company unveiling encouraging clinical news for its lead breast cancer drug candidate. Investors appeared to lock in profits or question how quickly the positive data might translate into commercial returns, putting pressure on the stock price.
The company reported strong topline Phase 3 VIKTORIA‑1 results in PIK3CA‑mutant HR+/HER2− advanced breast cancer, with gedatolisib regimens delivering meaningful progression‑free survival benefits over alpelisib combinations and showing good tolerability. Analysts may revisit their price targets as Celcuity plans an sNDA filing and prepares to present full data at ASCO, potentially reshaping expectations for the drug’s future sales.
More about Celcuity
YTD Price Performance: 21.67%
Average Trading Volume: 723,370
Technical Sentiment Signal: Buy
Current Market Cap: $5.87B
For further insights into CELC stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.